Tau PET/CT in Various Tau-Related Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-08-01

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the potential usefulness of 18F-S16/T807 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Beta Amyloid PET/CT in Various Aβ-Related Disease

NCT06725706

Amyloid Beta-Amyloid Neurodegenerative Diseases

RECRUITING

[18F]NIDF PET Imaging in Tau-related Diseases

NCT07306598

Neurodegenerative Disease Alzheimer s Disease Tauopathies

RECRUITING

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894

Alzheimer's Disease (AD) Parkinson's Disease (PD) Chronic Traumatic Encephalopathy (CTE) +4 more

COMPLETED PHASE1

Application of Multi-probe PET/MR Imaging in the Diagnosis and Evaluation of Alzheimer's Disease

NCT05003830

Alzheimer Disease PET/MR

UNKNOWN

Clinical Study of [18F] PM-PBB3 PET Imaging of Tau Protein in Neurodegenerative Diseases

NCT06344845

Neurodegenerative Diseases

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects with various Tau-related disease patients underwent 18F-S16/T807 PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-S16/T807 PET/CT were calculated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tauopathies Neurodegenerative Diseases Neurodegeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Group Assignment

Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.

18F-S16/T807

Intervention Type DIAGNOSTIC_TEST

Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18F-S16/T807

Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria

\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes